Jaka jest cena za Intellipharmaceutics International Inc. (IPCIF)

Cena za Intellipharmaceutics International Inc. (IPCIF) wynosi $0.15

Jaka jest kapitalizacja rynkowa dla Intellipharmaceutics International Inc. (IPCIF)

Kapitalizacja rynkowa dla Intellipharmaceutics International Inc. (IPCIF) wynosi $4.96M

Intellipharmaceutics International Inc. (IPCIF) EPS

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Rok	EPS	Zmień
2026 (TTM)	$-0.10	6.44%
2022	$-0.09	-11.09%
2021	$-0.10	-55.32%
2020	$-0.22	37.50%
2019	$-0.16	-94.44%
2018	$-2.88	0.00%
2017	$-2.88	-24.21%
2016	$-3.80	21.41%
2015	$-3.13	87.43%
2014	$-1.67	-71.40%
2013	$-5.84	64.04%
2012	$-3.56	9.54%
2011	$-3.25	-38.45%
2010	$-5.28	-8.65%
2008	$-5.78	-60.38%
2007	$-14.59	-77.93%
2006	$-66.11	-34.18%
2005	$-100.44	9.95%
2004	$-91.35	128.38%
2003	$-40.00	55.16%
2002	$-25.78	26.50%
2001	$-20.38	37.24%
2000	$-14.85	-19.64%
1999	$-18.48	0.00%

Rok

EPS

Zmień

2026 (TTM)

$-0.10

6.44%

2022

$-0.09

-11.09%

2021

$-0.10

-55.32%

2020

$-0.22

37.50%

2019

$-0.16

-94.44%

2018

$-2.88

0.00%

2017

$-2.88

-24.21%

2016

$-3.80

21.41%

2015

$-3.13

87.43%

2014

$-1.67

-71.40%

2013

$-5.84

64.04%

2012

$-3.56

9.54%

2011

$-3.25

-38.45%

2010

$-5.28

-8.65%

2008

$-5.78

-60.38%

2007

$-14.59

-77.93%

2006

$-66.11

-34.18%

2005

$-100.44

9.95%

2004

$-91.35

128.38%

2003

$-40.00

55.16%

2002

$-25.78

26.50%

2001

$-20.38

37.24%

2000

$-14.85

-19.64%

1999

$-18.48

0.00%

Firma	EPS	Różnica w EPS	Kraj
Novo Nordisk A/S NVO.US	$3.62	-3,881.11%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	$15.47	-16,248.23%	US
Regeneron Pharmaceuticals, Inc. REGN.US	$43.12	-45,110.44%	US
UCB SA UCB.BR	$9.62	-10,142.59%	BE
Argenx SE ARGX.US	$38.32	-40,100.00%	NL

Firma

EPS

Różnica w EPS

Kraj